{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:53:23Z","timestamp":1790974403388,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Oriental Talents Program Youth Project","award":["SSF828085"],"award-info":[{"award-number":["SSF828085"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52403213"],"award-info":[{"award-number":["52403213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272035"],"award-info":[{"award-number":["82272035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12275057"],"award-info":[{"award-number":["12275057"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010903","name":"Key Programme","doi-asserted-by":"publisher","award":["U23A20465"],"award-info":[{"award-number":["U23A20465"]}],"id":[{"id":"10.13039\/501100010903","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["ZCLMS26C1001"],"award-info":[{"award-number":["ZCLMS26C1001"]}],"id":[{"id":"https:\/\/ror.org\/04aqat463","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00259-026-07966-4","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:23:15Z","timestamp":1780471395000},"page":"6823-6836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translation of a novel EphA2-targeted PET tracer from preclinical models to first-in-human studies in pancreatic cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Xinyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-7522","authenticated-orcid":false,"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"7966_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: A Cancer J Clinic. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","DOI":"10.3322\/caac.21871"},{"key":"7966_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/s0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, Koerkamp BG, Seufferlein T, Wilmink JW, et al. Pancreatic cancer. Lancet. 2025;405:1182\u2013202. https:\/\/doi.org\/10.1016\/s0140-6736(25)00261-2.","journal-title":"Lancet"},{"key":"7966_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186:1729\u201354. https:\/\/doi.org\/10.1016\/j.cell.2023.02.014.","journal-title":"Cell"},{"key":"7966_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat reviews Clin Oncol. 2020;17:527\u201340. https:\/\/doi.org\/10.1038\/s41571-020-0363-5.","journal-title":"Nat reviews Clin Oncol"},{"key":"7966_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3322\/caac.21768","volume":"73","author":"EO Aboagye","year":"2023","unstructured":"Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: Making precision medicine possible. CA Cancer J Clin. 2023;73:255\u201374. https:\/\/doi.org\/10.3322\/caac.21768.","journal-title":"CA Cancer J Clin"},{"key":"7966_CR6","doi-asserted-by":"publisher","unstructured":"Ria T, Roy R, Mandal US, Sk UH. Prospects of nano-theranostic approaches against breast and cervical cancer. Biochimica et biophysica acta Reviews on cancer. 2024;1879:189227. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189227","DOI":"10.1016\/j.bbcan.2024.189227"},{"key":"7966_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.tips.2020.09.008","volume":"41","author":"AF Stoica","year":"2020","unstructured":"Stoica AF, Chang CH, Pauklin S. Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells. Trends Pharmacol Sci. 2020;41:977\u201393. https:\/\/doi.org\/10.1016\/j.tips.2020.09.008.","journal-title":"Trends Pharmacol Sci"},{"key":"7966_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","volume":"13","author":"Y Qian","year":"2020","unstructured":"Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13:130. https:\/\/doi.org\/10.1186\/s13045-020-00958-3.","journal-title":"J Hematol Oncol"},{"key":"7966_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat reviews Gastroenterol Hepatol. 2020;17:487\u2013505. https:\/\/doi.org\/10.1038\/s41575-020-0300-1.","journal-title":"Nat reviews Gastroenterol Hepatol"},{"key":"7966_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10585-006-9045-7","volume":"23","author":"SV Mudali","year":"2006","unstructured":"Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis. 2006;23:357\u201365. https:\/\/doi.org\/10.1007\/s10585-006-9045-7.","journal-title":"Clin Exp Metastasis"},{"key":"7966_CR11","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1038\/s41388-021-01714-8","volume":"40","author":"K Wilson","year":"2021","unstructured":"Wilson K, Shiuan E, Brantley-Sieders DM. Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene. 2021;40:2483\u201395. https:\/\/doi.org\/10.1038\/s41388-021-01714-8.","journal-title":"Oncogene"},{"key":"7966_CR12","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.3892\/mmr.2020.11384","volume":"22","author":"Q Wei","year":"2020","unstructured":"Wei Q, Wei L, Zhang J, Li Z, Feng H, Ren L. EphA2\u2013enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer. Mol Med Rep. 2020;22:2941\u20137. https:\/\/doi.org\/10.3892\/mmr.2020.11384.","journal-title":"Mol Med Rep"},{"key":"7966_CR13","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.7150\/thno.26650","volume":"8","author":"J Fan","year":"2018","unstructured":"Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, et al. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. Theranostics. 2018;8:5986\u201394. https:\/\/doi.org\/10.7150\/thno.26650.","journal-title":"Theranostics"},{"key":"7966_CR14","doi-asserted-by":"publisher","first-page":"15443","DOI":"10.1021\/acs.jmedchem.2c01391","volume":"65","author":"C Baggio","year":"2022","unstructured":"Baggio C, Udompholkul P, Gambini L, Pellecchia M, Targefrin. A Potent Agent Targeting the Ligand Binding Domain of EphA2. J Med Chem. 2022;65:15443\u201356. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01391.","journal-title":"J Med Chem"},{"key":"7966_CR15","doi-asserted-by":"publisher","first-page":"17103","DOI":"10.18632\/oncotarget.7931","volume":"7","author":"BA Quinn","year":"2016","unstructured":"Quinn BA, Wang S, Barile E, Das SK, Emdad L, Sarkar D, et al. Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Oncotarget. 2016;7:17103\u201310. https:\/\/doi.org\/10.18632\/oncotarget.7931.","journal-title":"Oncotarget"},{"key":"7966_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138290","author":"TY Le Large","year":"2020","unstructured":"Le Large TY, Mantini G, Meijer LL, Pham TV, Funel N, van Grieken NC, et al. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. JCI insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.138290. 5.","journal-title":"JCI insight"},{"key":"7966_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","volume":"13","author":"T Xiao","year":"2020","unstructured":"Xiao T, Xiao Y, Wang W, Tang YY, Xiao Z, Su M. Targeting EphA2 in cancer. J Hematol Oncol. 2020;13:114. https:\/\/doi.org\/10.1186\/s13045-020-00944-9.","journal-title":"J Hematol Oncol"},{"key":"7966_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncponc1041","volume":"5","author":"WA Weber","year":"2008","unstructured":"Weber WA, Grosu AL, Czernin J. Technology Insight: advances in molecular imaging and an appraisal of PET\/CT scanning. Nat Clin Pract Oncol. 2008;5:160\u201370. https:\/\/doi.org\/10.1038\/ncponc1041.","journal-title":"Nat Clin Pract Oncol"},{"key":"7966_CR19","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1007\/s00259-007-0503-5","volume":"34","author":"W Cai","year":"2007","unstructured":"Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, Tice DA, et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging. 2007;34:2024\u201336. https:\/\/doi.org\/10.1007\/s00259-007-0503-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7966_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2967\/jnumed.115.169839","volume":"57","author":"IJ Burvenich","year":"2016","unstructured":"Burvenich IJ, Parakh S, Gan HK, Lee FT, Guo N, Rigopoulos A, et al. Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2016;57:974\u201380. https:\/\/doi.org\/10.2967\/jnumed.115.169839.","journal-title":"Soc Nuclear Med"},{"key":"7966_CR21","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1007\/s00259-025-07139-9","volume":"52","author":"T Watabe","year":"2025","unstructured":"Watabe T, Iwasawa T, Kimura H, Shirakami Y, Naka S, Kaneda K, et al. Theranostics using (89)Zr\/(177)Lu-labeled antibody targeting erythropoietin-producing hepatocellular A2 (EphA2). Eur J Nucl Med Mol Imaging. 2025;52:2887\u201397. https:\/\/doi.org\/10.1007\/s00259-025-07139-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7966_CR22","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrclinonc.2016.119","volume":"13","author":"PP Adiseshaiah","year":"2016","unstructured":"Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat reviews Clin Oncol. 2016;13:750\u201365. https:\/\/doi.org\/10.1038\/nrclinonc.2016.119.","journal-title":"Nat reviews Clin Oncol"},{"key":"7966_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.nucmedbio.2014.03.020","volume":"41","author":"Y Liu","year":"2014","unstructured":"Liu Y, Lan X, Wu T, Lang J, Jin X, Sun X, et al. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor. Nucl Med Biol. 2014;41:450\u20136. https:\/\/doi.org\/10.1016\/j.nucmedbio.2014.03.020.","journal-title":"Nucl Med Biol"},{"key":"7966_CR24","doi-asserted-by":"publisher","unstructured":"Qu B, Li X, Ma Y, Wang Y, Han Y, Hou G et al. (68)Ga labeled EphA2-targeted cyclic peptide: a novel positron imaging tracer for triple-negative breast cancer? Dalton transactions (Cambridge, England: 2003). 2024;53:7946-52. https:\/\/doi.org\/10.1039\/d4dt00837e","DOI":"10.1039\/d4dt00837e"},{"key":"7966_CR25","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1021\/acs.jmedchem.9b02129","volume":"63","author":"GE Mudd","year":"2020","unstructured":"Mudd GE, Brown A, Chen L, van Rietschoten K, Watcham S, Teufel DP, et al. Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads. J Med Chem. 2020;63:4107\u201316. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b02129.","journal-title":"J Med Chem"},{"key":"7966_CR26","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.7150\/thno.106948","volume":"15","author":"AK Sharma","year":"2025","unstructured":"Sharma AK, Gupta K, Mishra A, Lofland G, Chen SY, Marsh I, et al. EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment. Theranostics. 2025;15:4229\u201346. https:\/\/doi.org\/10.7150\/thno.106948.","journal-title":"Theranostics"},{"key":"7966_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2967\/jnumed.124.269024","volume":"66","author":"L Sun","year":"2025","unstructured":"Sun L, Sun Y, Zuo K, Fan L, Wang X, Zhang J, et al. Pilot Study of Nectin-4-Targeted PET Imaging Agent (68)Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2025;66:473\u20139. https:\/\/doi.org\/10.2967\/jnumed.124.269024.","journal-title":"Soc Nuclear Med"},{"key":"7966_CR28","doi-asserted-by":"publisher","unstructured":"Zhang JP, Zhang YJ, Xu JY, Yang ZY. Radiation dosimetry estimates of [18F]-fluoroacetate based on biodistribution data of rats. Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine. 2012;70:332-5. https:\/\/doi.org\/10.1016\/j.apradiso.2011.09.025","DOI":"10.1016\/j.apradiso.2011.09.025"},{"key":"7966_CR29","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1007\/s00259-022-05729-5","volume":"49","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET\/MR and (18)F-FDG PET\/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:2877\u201388. https:\/\/doi.org\/10.1007\/s00259-022-05729-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7966_CR30","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s00259-021-05559-x","volume":"49","author":"NG Quigley","year":"2022","unstructured":"Quigley NG, Steiger K, Hober\u00fcck S, Czech N, Zierke MA, Kossatz S, et al. PET\/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the Cancer Integrin \u03b1v\u03b26 with Ga-68-Trivehexin. Eur J Nucl Med Mol Imaging. 2022;49:1136\u201347. https:\/\/doi.org\/10.1007\/s00259-021-05559-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7966_CR31","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1053\/j.semnuclmed.2025.06.011","volume":"55","author":"KM Pabst","year":"2025","unstructured":"Pabst KM, Fendler WP, Jochheim LS, Herrmann K. The Value of FAPI PET\/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update. Semin Nucl Med. 2025;55:701\u20139. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.06.011.","journal-title":"Semin Nucl Med"},{"key":"7966_CR32","doi-asserted-by":"publisher","unstructured":"Urso L, Napolitano R, Speltri G, Tuncel M, Badrane I, Uccelli L, et al. (68)Ga-Trivehexin: Current Status of \u03b1v\u03b26-Integrin Imaging and Perspectives. Cancers. 2025;17. https:\/\/doi.org\/10.3390\/cancers17091504.","DOI":"10.3390\/cancers17091504"},{"key":"7966_CR33","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1200\/jco.23.01107","volume":"42","author":"B Bashir","year":"2024","unstructured":"Bashir B, Wang JS, Falchook G, Fontana E, Arkenau HT, Carter L, et al. Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. J Clin oncology: official J Am Soc Clin Oncol. 2024;42:3443\u201352. https:\/\/doi.org\/10.1200\/jco.23.01107.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"7966_CR34","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.7150\/thno.96641","volume":"14","author":"M El Fakiri","year":"2024","unstructured":"El Fakiri M, Regupathy AR, Uhlmann L, Ayada N, Geis NM, Domogalla LC, et al. Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide. Theranostics. 2024;14:4701\u201312. https:\/\/doi.org\/10.7150\/thno.96641.","journal-title":"Theranostics"},{"key":"7966_CR35","doi-asserted-by":"publisher","first-page":"14623","DOI":"10.1021\/acs.jmedchem.3c01135","volume":"66","author":"Q Gan","year":"2023","unstructured":"Gan Q, Cui K, Cao Q, Zhang N, Yang MF, Yang X. Development of a (18)F-Labeled Bicyclic Peptide Targeting EphA2 for Molecular Imaging of PSMA-Negative Prostate Cancer. J Med Chem. 2023;66:14623\u201332. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01135.","journal-title":"J Med Chem"},{"key":"7966_CR36","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen X, Zaro JL, Shen WC. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013;65:1357\u201369. https:\/\/doi.org\/10.1016\/j.addr.2012.09.039.","journal-title":"Adv Drug Deliv Rev"},{"key":"7966_CR37","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1021\/bm500246w","volume":"15","author":"IW Hamley","year":"2014","unstructured":"Hamley IW. PEG-peptide conjugates. Biomacromolecules. 2014;15:1543\u201359. https:\/\/doi.org\/10.1021\/bm500246w.","journal-title":"Biomacromolecules"},{"key":"7966_CR38","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.2174\/138161210793292555","volume":"16","author":"L Gentilucci","year":"2010","unstructured":"Gentilucci L, De Marco R, Cerisoli L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Design. 2010;16:3185\u2013203. https:\/\/doi.org\/10.2174\/138161210793292555.","journal-title":"Curr Pharm Design"},{"key":"7966_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3892\/ol.2014.2196","volume":"8","author":"J Xu","year":"2014","unstructured":"Xu J, Zhang J, Cui L, Zhang H, Zhang S, Bai Y. High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome. Oncol Lett. 2014;8:687\u201392. https:\/\/doi.org\/10.3892\/ol.2014.2196.","journal-title":"Oncol Lett"},{"key":"7966_CR40","doi-asserted-by":"publisher","unstructured":"Ogawa K, Nishizawa K, Mishiro K, Munekane M, Fuchigami T, Echigo H, et al. Differences in the Renal Accumulation of Radiogallium-Labeled (Glu)(14) Peptides Containing Different Optical Isomers of Glutamic Acid. Molecules. 2024;29. https:\/\/doi.org\/10.3390\/molecules29173993.","DOI":"10.3390\/molecules29173993"},{"key":"7966_CR41","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.106.036020","volume":"48","author":"M Gotthardt","year":"2007","unstructured":"Gotthardt M, van Eerd-Vismale J, Oyen WJ, de Jong M, Zhang H, Rolleman E, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J nuclear medicine: official publication Soc Nuclear Med. 2007;48:596\u2013601. https:\/\/doi.org\/10.2967\/jnumed.106.036020.","journal-title":"J nuclear medicine: official publication Soc Nuclear Med"},{"key":"7966_CR42","doi-asserted-by":"publisher","unstructured":"de Roode KE, Joosten L, Behe M. Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands. Pharmaceuticals (Basel Switzerland). 2024;17. https:\/\/doi.org\/10.3390\/ph17020256.","DOI":"10.3390\/ph17020256"},{"key":"7966_CR43","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","volume":"51","author":"E Vegt","year":"2010","unstructured":"Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J nuclear medicine: official publication Soc Nuclear Med. 2010;51:1049\u201358. https:\/\/doi.org\/10.2967\/jnumed.110.075101.","journal-title":"J nuclear medicine: official publication Soc Nuclear Med"},{"key":"7966_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cbpa.2021.06.008","volume":"63","author":"DM Chigoho","year":"2021","unstructured":"Chigoho DM, Bridoux J, Hernot S. Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals. Curr Opin Chem Biol. 2021;63:219\u201328. https:\/\/doi.org\/10.1016\/j.cbpa.2021.06.008.","journal-title":"Curr Opin Chem Biol"},{"key":"7966_CR45","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.joms.2012.10.026","volume":"71","author":"Z Shao","year":"2013","unstructured":"Shao Z, Zhu F, Song K, Zhang H, Liu K, Shang Z. EphA2\/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland. J oral maxillofacial surgery: official J Am Association Oral Maxillofacial Surg. 2013;71:869\u201378. https:\/\/doi.org\/10.1016\/j.joms.2012.10.026.","journal-title":"J oral maxillofacial surgery: official J Am Association Oral Maxillofacial Surg"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07966-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:02:22Z","timestamp":1790971342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07966-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7966"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07966-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (Approval No. 2506323-21) and conducted in accordance with the Declaration of Helsinki. All animal experiments were approved by the Ethics Committee of Fudan University Shanghai Cancer Center (Approval No. FUSCC-IACUC-S2023-0003). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0\n                      \n                      .","order":2,"name":"Ethics","label":"Consent for publishing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}